A Comprehensive Digital Care Program for Migraine Management
Evaluation of a Comprehensive Digital Care Program for Migraine: A Prospective, Single-Arm, Pilot Study
研究概览
地位
详细说明
The Enso for Migraine program is a comprehensive digital care intervention consisting of: (1) an FDA-cleared neuromodulation wearable device for acute migraine pain relief; (2) guided exercise therapy playlists for migraine prevention; (3) a dedicated care team including a licensed physical therapist and health coach accessible through the Hinge Health app; (4) guided breathing exercises for relaxation and stress reduction; and (5) an in-app migraine trigger tracking journal and education library supporting behavioral awareness and self-management.
The study uses a prospective, single-arm, open-label design with within-subject comparison. Participants first complete a 28-day electronic diary (eDiary) baseline run-in period (weeks -4 to -1). Participants who log at least 4 migraine days and achieve at least 80% diary compliance (22 of 28 days) during the baseline period proceed to a 12-week intervention phase (weeks 1-12) with full program access. Participants continue daily eDiary throughout the intervention phase.
The primary objective is to evaluate the reduction in Monthly Migraine Days (MMDs) from the 28-day baseline to the final 28 days of the intervention (weeks 9-12). Secondary objectives include assessments of headache impact, work productivity, acute pain relief, and migraine responder rates.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
San Francisco、California、美国、94105
- Hinge Health, Inc.
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- 18 years of age or older
- Documented or clinical history of episodic or chronic migraine (with or without aura) for at least 12 months, consistent with ICHD-3 criteria. Verification of diagnosis must be established using one or more of the following methods: participant-provided medical records, documented pharmacy prescription history, or validated diagnostic screening instruments.
- Passes ID-Migraine Screener with a score of 2 or more "yes" answers to the following question: During the last 3 months, did you experience any of the following with your migraines? (1) Your migraines limited your ability to complete your daily activities for more than one day; (2) You felt nauseated or sick to your stomach; (3) Light bothered you (a lot more than when you don't have migraines).
- Migraine onset occurred at age 50 years or younger
- Minimum of 4 migraine days during the 28-day baseline run-in period, as confirmed by the study eDiary
- At least 80% eDiary compliance (minimum of 22 out of 28 days) during the prospective baseline run-in period
- Currently on a stable dose of traditional oral migraine preventive medication (e.g., topiramate, beta-blockers, amitriptyline) for at least 90 days prior to the start of the 28-day baseline period, or taking no preventive medication
- Currently on a stable dose of CGRP monoclonal antibodies (e.g., Aimovig, Emgality, Ajovy, Vyepti) or OnabotulinumtoxinA (Botox) for at least 180 days (6 months) prior to the start of the 28-day baseline period
- Willingness to maintain current preventive and as-needed (acute) medication regimens (e.g., triptans, NSAIDs, or abortive gepants) and refrain from initiating any brand new pharmacological or clinical treatments (e.g., nerve blocks, Botox, or infusions) for the duration of the 12-week intervention period
- Sufficient physical mobility to engage with the exercise therapy component of the program, with or without reasonable accommodations; participants reporting significant mobility restrictions (e.g., wheelchair use) will be eligible pending a clinical safety review by a Study Physician or Physical Therapist
- Active commercial health insurance coverage (either as the primary policyholder or a covered dependent) through an employer-sponsored health plan, commercial health insurer, or an affiliated benefit partner eligible for digital health solution deployment
- US resident
- Has a valid email account
- Personal ownership of a smartphone (iOS 15 or later, or Android 10 or later) with Bluetooth capability, app store access, and compatibility with the eDiary
- Able to understand and provide voluntary informed consent
Exclusion Criteria:
- Presence of a cardiac pacemaker, implanted or wearable defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other active implanted electronic medical device
- Presence of a metal implant in the head or neck (excluding dental work)
- Supraorbital nerve blocks or infusion treatments for migraine received within 4 months before the start of the baseline period
- Presence of other primary or secondary headache disorders (e.g., cluster headache, New Daily Persistent Headache, or post-traumatic headache); Note: Medication Overuse Headache (MOH) is NOT an exclusion criterion
- History of major head or neck injuries or any physical condition (e.g., severe cervical spine instability) that, in the opinion of the Principal Investigator and/or Study Physician, would make the exercise therapy component of the program unsafe; History of major cardiovascular events (e.g., stroke, arrhythmia, myocardial infarction)
- History of major migraine complications (e.g., migrainous infarction or aura-triggered seizure)
- Presence of fever, chills, or night sweats lasting five or more days and not improving
- Significant change in headache pattern, including headaches that are becoming much more severe or frequent, represent a new type of pain, wake the participant from sleep, or worsen with positional changes (e.g., coughing, bearing down, or changing position)
- Recent changes in vision, mental status, sensation, or strength; or new onset of jaw pain or neck stiffness
- Unexplained significant weight loss (past 3 months), or persistent weakness/numbness in the extremities (past 3 months)
- Known history of conditions that may compromise the immune system
- Head trauma within the past 2 weeks or diagnosis of a spinal fracture or shoulder dislocation within the past 3 months
- Any major trauma, fracture, or significant injury (e.g., car accident, sports injury) within the past 3 months
- Any major surgery within the past 3 months
- Inability to stand up from a chair without assistance (unless the participant utilizes a wheelchair and has been cleared via PT review)
- History of falling due to balance, weakness, vision, or other physical limitations within the past 3 months
- Current diagnosis of epilepsy or active malignancy (history of cancer within the last 5 years)
- Presence of a cognitive or neurological disorder (e.g., dementia, Parkinson's disease) that may interfere with study participation
- Currently unmanaged psychiatric disorder (e.g., schizophrenia, substance abuse, or severe major depressive disorder/anxiety) that, in the opinion of the investigator, could prevent compliance with study instructions
- Pregnant, planning to become pregnant during the study, or currently breastfeeding
- Currently institutionalized
- Insufficient proficiency with the English language to take part in study procedures or complete online surveys
- Current or previous enrollment in any Hinge Health Program or participation in prior Hinge Health research studies
- Current ownership or previous use of an Enso device or other prescribed high-frequency electrical stimulation therapy for the treatment of pain
- Participation in an investigational study within 30 days prior to screening
- Planned travel outside of the U.S. within the first month of enrollment
- Current employees or contractors of Hinge Health, Inc. or L&E Research, and their immediate family members
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Digital Care Program for Migraine Management
Participants complete a 28-day electronic diary (eDiary) baseline run-in period (weeks -4 to -1) and, if eligible, receive 12 weeks of access to the digital care program (weeks 1-12).
Participants continue daily eDiary throughout the intervention phase.
The program combines the FDA-cleared neuromodulation wearable device for acute migraine treatment with a digital care program delivered via the Hinge Health app.
|
The Neuromodulation Wearable Device is an FDA-cleared (510(k)) Class II neuromodulation wearable used for acute migraine treatment.
Participants use the device to treat migraine attacks as needed during the 12-week intervention phase.
A comprehensive digital care program delivered via the Hinge Health app, consisting of: (1) guided exercise therapy playlists targeting migraine prevention through structured physical activity; (2) a dedicated care team including a licensed physical therapist and health coach supporting clinical progress, adherence, and behavioral modification; (3) guided breathing exercises for relaxation and stress reduction; (4) in-app migraine trigger tracking allowing participants to log lifestyle, dietary, environmental, and hormonal factors associated with their episodes; and (5) a migraine-specific education library covering triggers, lifestyle modifications, sleep hygiene, and pain management strategies.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Change in Monthly Migraine Days (MMDs)
大体时间:From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
A migraine day is defined per ICHD-3 criteria as a calendar day with headache lasting at least 4 hours (untreated or unsuccessfully treated) with moderate-to-severe pain intensity, accompanied by nausea/vomiting or photophobia/phonophobia. Monthly Migraine Days are counted over a 28-day period using daily electronic diary data.
|
From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
50% Responder Rate
大体时间:From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
|
Mean Change in Monthly Headache Days (MHDs)
大体时间:From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
|
Mean Change in Migraine Pain Intensity (NRS)
大体时间:From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
|
Mean Change in Average Migraine Attack Duration
大体时间:From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
|
Mean Change in Headache Impact Test-6 (HIT-6) Score
大体时间:Baseline, Week 4, Week 8, Week 12
|
Baseline, Week 4, Week 8, Week 12
|
|
Proportion Achieving Acute Pain Relief at 2 Hours Post-Treatment
大体时间:During 12-week intervention phase
|
During 12-week intervention phase
|
|
Proportion Achieving Acute Pain Freedom at 2 Hours Post-Treatment
大体时间:During 12-week intervention phase
|
During 12-week intervention phase
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
Work Productivity and Activity Impairment (WPAI: Migraine)
大体时间:Baseline, Week 4, Week 8, Week 12
|
Baseline, Week 4, Week 8, Week 12
|
|
Patient Global Impression of Change (PGIC)
大体时间:Week 4, Week 8, Week 12
|
Week 4, Week 8, Week 12
|
|
Acute Migraine Medication Utilization
大体时间:From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
From the 28-day baseline run-in period to the final 28 days of the 12-week intervention (approximately 16 weeks total)
|
合作者和调查者
调查人员
- 首席研究员:Jeffrey Krauss, MD、Hinge Health, Inc
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.